Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q1 FY25 results · Apr–Jun 2024
Tatva Chintan Pharma Chem reported revenue from operations of ₹105.46 crore (down 7.8% from Q1 FY24) and net profit of ₹5.21 crore (down 45.2% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 105.46 | 114.36 | −7.8% | 98.27 | +7.3% |
| Other income | 1.17 | 1.01 | +15.6% | 4.53 | −74.1% |
| Total income | 106.64 | 115.38 | −7.6% | 102.79 | +3.7% |
| Profit before tax | 6.81 | 13.42 | −49.3% | 13.69 | −50.3% |
| Net profit for the period | 5.21 | 9.50 | −45.2% | 9.61 | −45.8% |
| EPS, basic (₹) | 2.23 | 4.29 | −48.0% | 4.11 | −45.7% |
| Net margin (%) | 4.9 | 8.3 | 9.8 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 93.81 | 106.11 | −11.6% | 93.93 | −0.1% |
| Other income | 1.42 | 1.01 | +39.9% | 4.53 | −68.6% |
| Total income | 95.23 | 107.12 | −11.1% | 98.46 | −3.3% |
| Profit before tax | 2.14 | 11.72 | −81.8% | 12.28 | −82.6% |
| Net profit for the period | 1.51 | 8.25 | −81.7% | 8.25 | −81.7% |
| EPS, basic (₹) | 0.64 | 3.72 | −82.8% | 3.52 | −81.8% |
| Net margin (%) | 1.6 | 7.8 | 8.8 |
Consolidated
- Filed with BSE
- 20 Aug 2024, 15:46 IST
- Board meeting
- 24 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Aug 2024, 15:46 IST
- Board meeting
- 24 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE